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ABSTRACT
Despite great advances in the fields of pain manage-
ment and palliative care, pain directly or indirectly
associated with a cancer diagnosis remains signifi-
cantly undertreated. The present paper reviews the
current standard for cancer pain management and
highlights new treatments and targeted interventional
techniques.
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1. INTRODUCTION
At least 70% of cancer patients will experience pain
at some point during the course of their illness 1,2.
Pain may arise directly from the underlying onco-
logic condition, and it may also result from the therapy
intended to modify the disease. The knowledge and
skill required to address cancer pain has evolved to
the point that effective pain management is consid-
ered by many to be a fundamental human right and
that failure to provide effective pain management is
considered to be poor medicine and unethical 3.
Although opioids remain the primary class of
medications indicated in the treatment of chronic can-
cer pain, greater attention has been given to the util-
ity of adjuvant analgesics. Different types of pain vary
in the extent to which they respond to various classes
of medications, suggesting the need for a clear un-
derstanding of pain pathophysiology and an individu-
alized management strategy. The present paper
reviews the basics of cancer pain management and
addresses some of the more complex clinical pain
syndromes, focusing on the medical and interven-
tional therapies currently available.
2. REVIEW OF THE BASICS IN CANCER PAIN
MANAGEMENT
Pain in patients with cancer is a symptom that can be
well managed, and yet it is a consistently undertreated
problem 2,3. Physician factors that have previously
been reported to hinder treatment of pain include
“difficulty with assessment” and “a lack of knowl-
edge about the many tools available to relieve this
symptom” 2,3.
The crucial initial step in effective pain manage-
ment is patient identification through inquiry and
observation. Identification can be achieved by uni-
versal implementation of valid screening tools. Fol-
low-up steps must include a detailed pain assessment
and accurate classification, which together will allow
the clinician to select the combination of therapies
most likely to provide relief.
2.1 Types of Cancer-Related Pain
Cancer-related pain can be classified into two main
types, nociceptive and neuropathic:
• Nociceptive pain occurs when tissues surround-
ing nociceptive fibres are injured or stressed.
Nociceptive pain can be further divided into so-
matic pain (which originates in the skin, bones,
joints, or muscles) and visceral pain (which origi-
nates in internal organs) 1. Patients with somatic
pain are usually able to localize the pain well.
They will often report an ache that worsens with
movement of, or pressure on, the affected area.
Visceral pain, usually described as a cramping or
pressure-like pain, is often not well localized 1.
• Neuropathic pain is pain related to damage or
dysfunction of the nervous system, and this pain
type is described in more detail in its own sub-
section, later in this article.
Patients may simultaneously experience more
than one type of pain at more than one location, with
each pain being likely to respond in varying degrees
to various therapies.
2.2 The Analgesic Ladder
In an attempt to simplify pain management for clini-
cians, the World Health Organization devised a
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medication algorithm known as the “3-step analge-
sic ladder” 4. In brief, if medications are required to
treat mild cancer pain, non-opioids (acetaminophen,
acetylsalicylic acid) should first be introduced. If pain
persists, or if at presentation it is moderate to severe,
opioids should be introduced. Initially, “weak opio-
ids” (codeine, tramadol) should be prescribed; if
maximum doses are reached, the weak opioids should
be rotated to “strong opioids.” The strong opioids
include morphine, oxycodone, hydromorphone, fen-
tanyl, and methadone.
On their own, the strong opioids have no maxi-
mum dose. But it is important to note that, although
oxycodone is a strong opioid, dosing for combina-
tion products containing both short-acting oxycodone
and acetaminophen is limited by the maximum al-
lowable daily dose of acetaminophen. Such combi-
nation agents are therefore considered appropriate for
step 2 of the analgesic ladder.
Although meperidine is considered a strong
opioid, it is not used in the cancer pain setting, be-
cause consistent use leads to the accumulation of
normeperidine in the body and a lowering of the sei-
zure threshold 5.
Table I outlines practical suggestions for initiat-
ing opioids.
2.3 General Dosing Considerations for Analgesics
If around-the-clock dosing of short-acting opioids is
required, the patient should receive a dose every
4 hours 6. Most short-acting opioids have a half-life
of 3–4 hours, and for oral preparations, the maximum
concentration is reached within 60 minutes (30 min-
utes by the subcutaneous route, 15 minutes by the
intravenous route) 6,7.
“Breakthrough pain” refers to pain experienced
despite around-the-clock analgesia. Given the time
required to reach maximum concentration, a break-
through dose should be available to patients once
every hour. When initiating an opioid, calculate the
breakthrough dose to be at least half of the routine
4-hourly dose, or 10%–20% of the total daily dose
of opioid 2.
Long-acting or extended-release opioids have a
half-life of approximately 12 hours; most patients
should therefore receive them twice daily 8. Long-
acting formulations should not be used on an as-
needed basis because of their delayed onset of
action.
In general, patients should receive the same
opioid for routine and breakthrough dosing. The ex-
ception is fentanyl, because a breakthrough form is
not currently available in Canada. Although on its
own fentanyl is a short-acting opioid, it is commonly
used in the form of a transdermal patch 6. Patches
form a depot under the skin, which slowly releases
fentanyl into the subcutaneous tissue and thence into
the bloodstream. Pain relief from a fentanyl patch
begins 8–12 hours after application, and the patch
needs to be changed once every 72 hours 6. A recent
report from the Institute for Safe Medication Prac-
tices reminded clinicians that fentanyl patches should
not be used in the setting of acute pain or for patients
who are opioid-naïve 9.
Table II provides an overview of equianalgesic
dosing for cases in which opioid rotation is required.
There is no consistency in reported ratios, and de-
spite oversimplification, sufficient evidence exists to
support the numbers used in the table 2,5,6. Because
of a nonlinear ratio with other opioids, fentanyl is
not included.
If pain begins to stabilize on a routine dose of a
short-acting opioid, the long-acting equivalent of the
same opioid should be substituted. The availability
of hourly breakthrough dosing should not change.
Whenever possible, opioid side effects should be
prevented 10–12. Table III summarizes common side
effects and suggests management strategies. Nota-
bly, nausea and sedation often resolve within 3–
5 days, but ongoing prevention of constipation
essential. Stool softeners, stimulant laxatives, and if
needed, osmotic laxatives should be prescribed with
every opioid initiation.
TABLE II Opioid equianalgesics
Drug Dose
Oral Subcutaneous
Codeine 100 mg —
Morphine 10 mg 5 mg
Oxycodone 5 mg —
Hydromorphone 2 mg 1 mg
TABLE I Summary of opioid dosing in cancer pain management
Initial dosage of “strong opioid” in opioid-naive patient:
Fit patient: Morphine 5 mg orally every 4 hours or equivalent
Frail patient: Morphine 2.5 mg orally every 4 hours or equivalent
Thereafter, titrate to pain relief or unacceptable side effects.
Fentanyl patches should not be prescribed for the opioid-naive patient. (If patients are on “weak opioids”—for example, Tylenol 3,
combined acetaminophen–oxycodone—they are not opioid-naïve!)
Dosage of “strong opioid” in patients already on opioids (including “weak opioids”):
Determine starting dose of “strong opioid” by using equianalgesic table.
When rotating opioids, reduce the calculated dose of the new opioid by approximately 30% (incomplete cross tolerance).MYERS and SHETTY
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3. AGENTS FOR SPECIAL TYPES OF
CANCER PAIN
3.1 Bony Pain
The effective management of cancer pain related to
primary or metastatic bony disease may include
classes of analgesic drugs other than opioids—for
example, acetaminophen and nonsteroidal anti-in-
flammatory drugs (NSAIDs) 13. The use of NSAIDs tends
to be limited by side effects and concerns about gas-
trointestinal and renal toxicity. The utility of these
drugs initially improved with the advent of the
cyclooxygenase-2 selective inhibitors, which lack
significant gastrointestinal and renal toxicity, but re-
cent associations with heart disease may affect avail-
ability 14,15.
Strong evidence exists for the use of bisphos-
phonates to reduce metastatic bone pain associated
with lung, prostate, and renal cancers 16. The more
potent bisphosphonates (pamidronate, zoledronate,
and ibandronate) elicit more durable responses than
clodronate does 16. The optimum dose and duration
of treatment are unknown; however, loading doses
(particularly of ibandronate) can reduce refractory
bone pain within days 16. Side effects are mild, but
renal function must be monitored, particularly with
zoledronate 13,16.
3.2 Neuropathic Pain
The possible neuropathic component of cancer pain
is frequently underdiagnosed or inadequately
treated—or both 17. Patients may have great difficulty
finding words to describe the sensation, but they may
use terms such as “aching,” “burning,” “stabbing,”
or “pressure-like.” The description may include a
component of “shooting” or “radiating” and the lo-
cation can be anywhere in the dermatomal region
innervated by the damaged neural structure.
Several mechanisms have been proposed to me-
diate nerve damage or injury expression 18. Periph-
erally, regeneration after nerve damage can result in
the development of neuroma and uncontrolled neu-
ronal firing. This process is thought to be mediated
mainly through increased expression of both sodium
and voltage-gated calcium channels; hence, these
receptors have become the main target of several
drugs intended to alter the expression of neuropathic
pain. Serotonin and norepinephrine are known to pre-
synaptically mediate descending inhibition of ascend-
ing pain pathways in the brain and spinal cord,
creating a second target for neuropathic analgesics.
In addition, heightened sensitivity of spinal neurons
is mediated by the N-methyl-D-aspartic acid (NMDA)
receptor, making for a third target.
Although often used as first-line therapy, opioids
may have limited efficacy in the management of neu-
ropathic pain 19–21. As a result, improved pain man-
agement may be achieved by introducing medications
that target one or more of the foregoing pathways.
3.2.1 Anticonvulsants
Gabapentin: Gabapentin, first licensed in 1994, was
designed as a g-aminobutyric acid analogue intended
to reduce seizure activity 22. Several mechanisms have
been postulated to explain the utility of gabapentin
in the setting of neuropathic pain. It is known to act
centrally at the level of the dorsal horn neurons by
binding to calcium channels. It requires 3-times-daily
dosing and is excreted unchanged by the kidneys,
requiring dosing adjustment in the setting of renal
insufficiency 23. Because no enzymatic metabolism
occurs in the liver, gabapentin has no significant drug
interactions.
TABLE III Common opioid side effects and suggested management strategies
Side effect Management strategy
Nausea Haloperidol 0.5 mg as needed
Prochlorperazine 10 mg as needed
Sedation Educate and reassure as to transient nature of effect
For persistent sedation, decrease dose, rotate opioid, or consider stimulant (methylphenidate)
Constipation Stool softener (docusate), plus stimulant laxative (senna) given routinely
Urinary retention Decrease dose or rotate opioid
Pruritus Antihistamine
Consider rotation to synthetic opioid
Opioid toxicity Decrease opioid dose
(respiratory depression, a Consider opioid rotation
delirium, myoclonus, Maximize adjuvant analgesics
hyperalgesia, seizure, Reserve use of naloxone for diagnostic purposes and in setting of severe toxicity only
pinpoint pupils) Rule out sepsis, hypercalcemia, or other metabolic disturbances that may have predisposed
a Fear of respiratory depression is a common barrier to aggressive pain managment. Although respiratory depression is a serious side effect,
it is quite rare in patients whose opioids have been appropriately titrated. Tolerance with regard to respiratory depression follows
downregulation of the m 2 agonist receptor subtype. Downregulation occurs rapidly when opioid dosing is routine.CANCER PAIN MANAGEMENT
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No randomized trials have examined the efficacy
of gabapentin in the setting of cancer pain. In the
management of diabetic neuropathy, gabapentin pro-
duces greater pain control with fewer side effects than
amitriptyline does 24. The dosing schedule in Table IV
addresses both the pharmacodynamics and the po-
tential side effect of somnolence.
Pregabalin: Structurally similar to gabapentin,
pregabalin was designed to have greater bioavail-
ability and a greater affinity for the same calcium
channels blocked by gabapentin 25. The linear phar-
macokinetics of pregabalin allow both for twice-daily
dosing and for more rapid titration than are seen with
gabapentin 26. Clinical efficacy is apparent within
1 week, and with gabapentin, pregabalin must be
dose-adjusted in the setting of renal insufficiency 26.
Starting doses tend to be 75 mg twice daily, with ti-
tration to a maximum total daily dose of 600 mg.
In the setting of cancer pain management, clini-
cal efficacy comparisons have not been made between
gabapentin and pregabalin. If either gabapentin or
pregabalin must be discontinued, the drug should be
tapered over a 1- to 3-week period to prevent with-
drawal syndrome (symptoms of which include nau-
sea, headache, diarrhea).
Clinicians must educate themselves regarding
medication reimbursement issues, because many drug
benefit plans will not cover gabapentin or pregabalin
for neuropathic pain unless documentation of poor
response to less-expensive medications is provided.
Other anticonvulsants: Agents including carba-
mazepine, phenytoin, valproate, and clonazepam are
occasionally used in the setting of cancer pain, but
evidence for their benefit is limited 27. Potential side
effects and drug interactions often limit the clinical
utility of these agents, but they should be considered
for complex neuropathic pain syndromes.
3.2.2 Antidepressants
First reported to reduce neuropathic pain in 1977,
tricyclic antidepressants (TCAs) are commonly used
in the setting of cancer pain 28. No single TCA has been
found to have greater efficacy than any other for neu-
ropathic pain; side effects tend to be the limiting fac-
tor in titrating. Nortriptyline tends to have the least
anticholinergic properties, and the initiating dose
should be 10–25 mg once daily, taken at night.
The newer selective serotonin (and serotonin–
norepinephrine) reuptake inhibitors, have been stud-
ied in the setting of diabetic neuropathy and trigeminal
neuralgia. There is moderate evidence that these
medications can provide can provide relief from neu-
ropathic pain; however, TCAs remain the antidepres-
sant of choice 29,30.
3.2.3 Corticosteroids
Corticosteroids possess analgesic properties for sev-
eral cancer pain syndromes, including both neuro-
pathic and bony pain 31. The risk of adverse effects
increases with dose and duration of therapy alike;
however, these medications may contribute to sub-
stantial relief in the setting of acute pain. Corticos-
teroids should be tapered when implementing the
long-term management plan.
3.2.3 Methadone
Developed in Germany during World War II, metha-
done was initially designed for use in pain manage-
ment; however, for several decades, this synthetic
opioid was used preferentially in the clinical setting
of opioid addiction 32. Recently, though, with im-
proved understanding of methadone’s complex phar-
macodynamic and pharmacokinetic properties, the
compound is rapidly becoming an essential tool in
the management of complex cancer pain.
Methadone exists as a racemic compound: one
isomer is a m-receptor agonist; the other is respon-
sible for inhibition of the NMDA receptor and the pre-
synaptic reuptake of both norepinephrine and
serotonin 33. For patients with a neuropathic compo-
nent to their cancer, methadone may have a signifi-
cant role.
Methadone’s rapid absorption is followed by tis-
sue distribution and a highly variable elimination
phase intended to maintain plasma levels. The result-
ing half-life varies greatly—from 4 hours to
120 hours—among individuals 33. Because of this
variability (and even in the absence of dose adjust-
ment), the possibility of unexpected toxicity exists
for several days after dosing is initiated.
Methadone is metabolized in the liver via the cy-
tochrome P450 system, specifically the CYP3A4
group of enzymes 33. Although not a comprehensive
list, Table V highlights some of the important drug
interactions.
Methadone has no active metabolites, and no ad-
justments in dosing need be made in the setting of
renal insufficiency. The same formulation of metha-
done is used for both routine and breakthrough dosing.
Because of methadone’s complex pharmacodynamics
and pharmacokinetics, breakthrough dosing differs
from that of other opioids, tending to be offered every
3 hours at maximum. The onset of analgesia with
methadone is 20–30 minutes for oral preparations, and
routes of administration include rectal, subcutaneous,
intravenous, epidural, and intrathecal 33.
TABLE IV Suggested titration of gabapentin in setting of neuropathic
pain
Day 1 Initiate 300 mg at half strength for 3 days
Day 4 Increase to 300 mg twice daily for 3 days
Day 7 Increase to 300 mg three times daily
Subsequent days Continue to titrate based on response to a
maximum of 3600 mg daily a
a In setting of normal creatinine clearance.MYERS and SHETTY
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Several models for rotating to methadone from
another opioid have been devised 34–36. The equi-
analgesic ratio and subsequent methadone dosing regi-
men depend on both the duration of exposure and the
dose of the patient’s current opioid. The complexity
involved in prescribing methadone for pain manage-
ment in Canada means that both a specialized federal
license and an identified mentor are required.
Methadone is available at very low cost, which
makes it an attractive medication for pain manage-
ment in developing countries. One study compared
methadone with morphine as a first-line opioid agent
and found equal efficacy in the setting of cancer pain
for opioid-naïve patients 37.
Case study: Mike, a 33-year-old man with recurrent
metastatic rectal carcinoma presents with severe burn-
ing rectal pain. He is unable to sit for more than
30 minutes at a time despite titration of both his long-
acting hydromorphone to 84 mg three times daily and
gabapentin to 1200 mg three times daily. Opioid ro-
tation to methadone proved somewhat beneficial,
because at a dose of 50 mg three times daily, Mike
was able to cut back his breakthrough requirement
during the day to four 15-mg doses of methadone.
He was referred to interventional anesthesia for an
impar ganglion block.
3.2.4 Interventional Cancer Pain Management
Despite use of the original World Health Organiza-
tion three-step analgesic ladder for cancer pain man-
agement (that is, appropriate oral opioid use), up to
25% of people with cancer may continue to experi-
ence pain 2,38. In 1996, a fourth step, “invasive
therapy” was added to the guidelines 39. Invasive
therapy (“interventions”) should be considered for
patients whose pain is not responding to escalating
doses of opioids and adequate adjuvant medication,
whose pain is likely to be opioid-insensitive (that is,
has a neuropathic component or is secondary to bony
metastases, and so on), or in whom analgesia is pro-
ducing intolerable side effects 40. Because of the com-
plexity of the pain syndromes requiring interventions,
the interventional procedures should be thought of
as adjuvants to standard analgesic regimens. If re-
sources permit, they should be used as soon as the
necessity becomes clear.
Neurolysis attempts to interrupt the neural path-
way thought to be responsible for the pain syndrome.
This interruption can be achieved through anesthe-
sia, including chemical (injection of agents), thermal
(cryoablation and radiofrequency), and surgical (cor-
dotomy) techniques 40. The sympathetic chain runs
along the vertebral column and makes a good target
for intervention at the level determined to be appro-
priate for the specific pain complaint. Table VI out-
lines the five main sites for potential block, with their
associated pain syndromes.
Continuous epidural, subarachnoid, or intrathe-
cal infusion of an opioid and adjuvants as required is
now routinely considered in the management of pa-
tients with refractory cancer pain 40. The usual indi-
cation is pain in the lower half of the body that cannot
be managed at opioid doses below those associated
with intolerable and unmanageable somnolence or
cognitive impairment 41. The addition of a local an-
esthetic or other drug to the opioid may provide sig-
nificant analgesia when intraspinal opioids alone are
insufficient 42. The limiting factors tend to be inpa-
tient or outpatient resources.
Case study: Jim, a 45-year-old man with metastatic
renal cell carcinoma to the pelvis, describes severe,
deep, stabbing pain in the right buttock that radiates
down the right leg. Trials of several opioids in com-
bination with neuropathic adjuvants have not brought
his pain below a 5 on a pain scale of 10. Sativex (GW
Pharmaceuticals, Salisbury, U.K.) and oral ketamine
were added to his regimen of methadone and
pregabalin, and he is being considered for an intraspi-
nal technique.
3.2.5 Cannabinoids
In Canada, the first buccal cannabinoid spray
(Sativex) was recently approved for use in cancer
pain. The cannabinoid CB1 receptor acts on path-
ways that partly overlap with those affected by opio-
ids. It is widely distributed throughout the central and
peripheral nervous systems 43. Cannabinoids and
opioids may have additive or synergistic analgesic
effects because of similarities in the physical distri-
bution of their receptors 44. Cannabinoids have an
analgesic effect equal to that of codeine, and in the
setting of cancer pain, cannabinoids may have a role
in management of a neuropathic component 44–47.
Sativex is sprayed into the mouth, under the tongue,
or onto the inside of the cheek. The starting dose for
an adult is not more than 1 spray every 4 hours, to a
TABLE V Clinically significant drug–drug interactions with methadone
Clinically significant CYP3A4 inducers Amprenavir, efavirenz, nelfinavir, nevirapine, phenobarbital, phenytoin,
(that is, they lower methadone concentration) rifampin, ritonavir
Possibly clinically significant CYP3A4 inducers Carbamazepine, chronic ethanol
Clinically significant CYP3A4 inhibitors Benzodiazepines, ciprofloxacin, ethanol, fluconazole
(that is, they increase methadone concentration)
Possibly clinically significant CYP3A4 inhibitors Cimetidine, fluoxetine, omeprazole, quinidine, paroxetineCANCER PAIN MANAGEMENT
CURRENT ONCOLOGY—VOLUME 15, SUPPLEMENT 1
S46
maximum of 4 sprays, on the first day. In patients
with cancer, the average dose of Sativex is 8 sprays
spread evenly throughout the day.
3.2.6 Ketamine
Ketamine has been used with some success to re-
duce the dose of opioid and to improve pain control
in the setting of cancer pain 48–50. It acts on the cen-
tral nervous system in numerous ways, but its effect
as a NMDA receptor antagonist is thought to be re-
sponsible for its utility in treating opioid-resistant
neuropathic pain 51. Trials involving patients with
cancer-related pain have been performed with
ketamine administered in a variety of dosing sched-
ules and routes (intrathecal, epidural, intravenous,
subcutaneous, and oral), but there is uncertainty
about the conversion ratios between parenteral and
oral preparations. Most trials of ketamine have in-
volved relatively low numbers of subjects, but they
have shown dramatic reductions in pain with its
use 52.
Adverse effects that have been reported with
ketamine include tachycardia, hypertension, raised
intracranial pressure, and nausea, but the ones that
raise the most concern are the psychotomimetic ef-
fects such as hallucinations, confusion, and sedation.
In some patients, these effects can be avoided by
administering haloperidol or a benzodiazepine as a
prophylactic 52. However, until more evidence is
available, a sensible precaution would be to use
ketamine only in patients that have poor pain con-
trol despite escalating opioid doses and attempts at
opioid rotation. The safest locale for a ketamine trial
is an inpatient setting, in which patients can be moni-
tored for adverse effects and doses can be titrated
carefully. Careful titration is necessary because, de-
spite its rapid onset of action, ketamine reaches its
peak analgesic effect many hours after administra-
tion 50. At a dose of 0.5–4.5 mg/kg, a patient can
experience anaesthesia while remaining conscious.
Lowering the dose to an hourly 0.1–0.3 mg/kg makes
ketamine a useful analgesic 50. Protocols for the ini-
tiation of a continuous infusion of ketamine are avail-
able 50. Hospitalization and specific monitoring are
required, but continuous infusion has been shown to
be a successful option for refractory pain in the can-
cer patient. Oral ketamine may have a role in cancer
pain management, but has not been well studied 53.
3.2.7 Tramadol
Tramadol exists as a racemic compound: one iso-
mer is both a weak m-receptor agonist and a seroto-
nin reuptake inhibitor 54; the other isomer inhibits
reuptake of norepinephrine. The M1 product of me-
tabolism has six times tramadol’s affinity for the
m-receptor 54. These pharmacokinetic and pharma-
codynamic properties suggest that tramadol may
have a significant role in the management of cancer
pain in the patient describing a strong neuropathic
component.
Tramadol has few drug interactions; a notable
exception occurs with antidepressants. Caution must
be used if a combination of tramadol and either TCAs
or selective serotonin reuptake inhibitors is being
considered; patients receiving combinations of this
kind are at great risk of seizure 54. Tramadol should
not be used in the setting of advanced renal insuffi-
ciency (creatinine clearance below 30 mL/min) or
advanced cirrhosis.
Tramadol is available in an extended-release form
that is given once daily. Maximum doses of tramadol
should not exceed 600 mg daily, and for opioid-naïve
individuals, the typical starting total daily dose is
150 mg. The side effects of tramadol are similar to
those of other opioids (nausea, sedation, dizziness),
with the exception of constipation, which has been
found to be significantly less with tramadol than with
other opioids 54.
In head-to-head trials, tramadol at high doses has
been found to have efficacy equivalent to that of low-
dose morphine. The equianalgesic ratio between
tramadol and morphine has not been consistently
described and falls into the range 4:1–15:1 in the lit-
erature 55–57 One head-to-head trial that also included
buprenorphine demonstrated equivalent efficacy be-
tween the two agents; however, tramadol demon-
strated a more tolerable side effect profile 58.
3.2.8 Buprenorphine
Buprenorphine, a synthetic opioid, was developed in
the 1960s as a partial m-receptor agonist 59. Its oral
bioavailability is poor, but after development of an
associated transdermal delivery system, it was re-
cently reintroduced in cancer pain management. Un-
like other transdermal preparations, the polymer
matrix system for buprenorphine prevents dose dump-
ing if the integrity of the patch is compromised 60.
TABLE VI Common locations along the sympathetic chain amenable to neurolysis
Sympathetic ganglia Pain syndrome
Cervicothoracic (stellate) ganglion Neuropathic pain from head and neck cancers, post-mastectomy pain, superior sulcus syndrome
Celiac plexus Upper abdominal or back pain associated with cancer of the esophagus, pancreas, liver, or stomach
Lumbar ganglia Flank pain or lower abdominal pain from urologic cancers
Superior hypogastric plexus Lower pelvic pain from colon, rectal, or gynecologic cancers
Ganglion impar Perineal and rectal pain from anal or rectal cancerMYERS and SHETTY
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Clinically, the medication has a ceiling effect at higher
doses; this effect is thought to be related to activa-
tion of the opioid receptor–like receptor (known to
reverse analgesia, producing a counter-opioid re-
sponse). Buprenorphine is metabolized through the
enzyme system that also metabolizes methadone, and
it shares the drug interactions that cause concern with
methadone administration. The side effects that pa-
tients describe are similar to those seen with other
opioids, but as with tramadol, buprenorphine is less
associated with constipation 61. Patch strengths in-
clude 5, 10, and 20 mg per hour. Buprenorphine’s
equianalgesic ratio with morphine has not been well
described.
Studies in the cancer pain population are limited,
but one head-to-head study versus morphine in
chronic pain demonstrated significantly greater effi-
cacy and few side effects with buprenorphine 62.
3.3 Treatment-Related Pain Syndromes
Chronic pain syndromes related to treatment (sys-
temic therapy, radiation, surgery) are mostly neuro-
pathic in classification 63. The predisposing factors
for chronic neuropathic pain following nerve injury
are unknown. Any surgical incision, even a minor
one, can induce a neuropathic pain syndrome. Ra-
diation-induced fibrosis can cause peripheral nerve
injury. The resulting chronic neuropathic pain usu-
ally appears months or years after treatment 64. In
contrast to nerve injury related to neoplasm, the pain
is generally less prominent and slowly progressive.
It is often associated with weakness, sensory dis-
turbances, radiation changes of the skin, and lymphe-
dema. Painful dysesthesias, paresthesias, cramps,
and restless legs associated with mild weakness, sen-
sory loss, or autonomic dysfunction may follow
treatment with neurotoxic chemotherapy (for ex-
ample, vincristine, cisplatin, paclitaxel). Although
most patients report gradual improvement after
therapy is discontinued, some develop a persistent,
painful polyneuropathy 63.
The treatment algorithm for post-treatment neu-
ropathic pain syndromes is different from that for pain
directly related to neoplastic disease, in that first-line
medications tend to be anticonvulsants or antidepres-
sants 65. Patients with this type of pain may best be
managed in the chronic pain clinic setting.
4. EDUCATION OF PATIENTS, CAREGIVERS,
AND CLINICIANS
Appropriate use of medications and provision of edu-
cation to dispel the fears and myths surrounding opio-
ids are crucial components of a cancer pain
management strategy. Among clinicians, fears regard-
ing side effects, misconceptions about addiction, and
negative previous experiences have been shown to
greatly influence opioid prescribing habits 66. A sur-
vey by the physicians of the Eastern Cooperative
Oncology Group showed that 30% of respondents
would not use “strong analgesics” if a patient was
expected to survive for more than 6 months, suggest-
ing several unfounded barriers. When opioids are
used properly, fewer than 1% of patients with cancer
exhibit behaviours consistent with addiction 11,67.
Attention to the prevention and management of opioid
side effects is needed, but should not delay response.
With respect to management of pain in cancer pa-
tients, clinicians must routinely assess for barriers that
are easily overcome with reassurance and education.
5. SUMMARY
Given current understandings of the pain pathways
in the body and the cadre of medications and inter-
ventions available that may provide complete re-
lief, patients living with cancer should not
unnecessarily live with pain. Clinicians have a duty
to manage this symptom with intensity and aggres-
sion equal to that applied to the cancer itself. With
increased education, it is to be hoped that health
care professionals will develop greater comfort in
using opioids, will introduce adjuvant analgesics ap-
propriately, and will refer to palliative care col-
leagues when pain or related symptoms in their
patients are not well controlled.
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